Large contribution of human papillomavirus in vaginal neoplastic lesions: A worldwide study in 597 samples
Identifieur interne : 000130 ( Main/Exploration ); précédent : 000129; suivant : 000131Large contribution of human papillomavirus in vaginal neoplastic lesions: A worldwide study in 597 samples
Auteurs : RBID : Pascal:14-0256885Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Vaccin.
English descriptors
- KwdEn :
Abstract
Aim: This work describes the human papillomavirus (HPV) prevalence and the HPV type distribution in a large series of vaginal intraepithelial neoplasia (VAIN) grades 2/3 and vaginal cancer worldwide. Methods: We analysed 189 VAIN 2/3 and 408 invasive vaginal cancer cases collected from 31 countries from 1986 to 2011. After histopathological evaluation of sectioned formalin-fixed paraffin-embedded samples, HPV DNA detection and typing was performed using the SPF-10/DNA enzyme immunoassay (DEIA)/LiPA25 system (version 1). A subset of 146 vaginal cancers was tested for p16INK4a expression, a cellular surrogate marker for HPV transformation. Prevalence ratios were estimated using multivariate Poisson regression with robust variance. Results: HPV DNA was detected in 74% (95% confidence interval (CI): 70-78%) of invasive cancers and in 96% (95% CI: 92-98%) of VAIN 2/3. Among cancers, the highest detection rates were observed in warty-basaloid subtype of squamous cell carcinomas, and in younger ages. Concerning the type-specific distribution, HPV16 was the most frequently type detected in both precancerous and cancerous lesions (59%). p16INK4a overexpression was found in 87% of HPV DNA positive vaginal cancer cases. Conclusions: HPV was identified in a large proportion of invasive vaginal cancers and in almost all VAIN 2/3. HPV16 was the most common type detected. A large impact in the reduction of the burden of vaginal neoplastic lesions is expected among vaccinated cohorts.
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Large contribution of human papillomavirus in vaginal neoplastic lesions: A worldwide study in 597 samples</title><author><name sortKey="Alemany, L" uniqKey="Alemany L">L. Alemany</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>9 aut.</sZ><sZ>14 aut.</sZ><sZ>33 aut.</sZ><sZ>35 aut.</sZ><sZ>36 aut.</sZ></inist:fA14><country>Espagne</country><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CIBER en Epidemiología y Salud Pública (CIBERESP)</s1><s3>ESP</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>35 aut.</sZ></inist:fA14><country>Espagne</country><wicri:noRegion>CIBER en Epidemiología y Salud Pública (CIBERESP)</wicri:noRegion></affiliation></author><author><name sortKey="Saunier, M" uniqKey="Saunier M">M. Saunier</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>9 aut.</sZ><sZ>14 aut.</sZ><sZ>33 aut.</sZ><sZ>35 aut.</sZ><sZ>36 aut.</sZ></inist:fA14><country>Espagne</country><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Tinoco, L" uniqKey="Tinoco L">L. Tinoco</name><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Hospital Oncológico</s1><s2>Quito</s2><s3>ECU</s3><sZ>3 aut.</sZ></inist:fA14><country>Équateur</country><wicri:noRegion>Hospital Oncológico</wicri:noRegion></affiliation></author><author><name sortKey="Quiros, B" uniqKey="Quiros B">B. Quiros</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>9 aut.</sZ><sZ>14 aut.</sZ><sZ>33 aut.</sZ><sZ>35 aut.</sZ><sZ>36 aut.</sZ></inist:fA14><country>Espagne</country><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Alvarado Cabrero, I" uniqKey="Alvarado Cabrero I">I. Alvarado-Cabrero</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Mexican Oncology Hospital, IMSS</s1><s2>Mexico, DF</s2><s3>MEX</s3><sZ>5 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Mexique</country><wicri:noRegion>Mexico, DF</wicri:noRegion></affiliation></author><author><name sortKey="Alejo, M" uniqKey="Alejo M">M. Alejo</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>9 aut.</sZ><sZ>14 aut.</sZ><sZ>33 aut.</sZ><sZ>35 aut.</sZ><sZ>36 aut.</sZ></inist:fA14><country>Espagne</country><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation><affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Hospital General de L'Hospitalet</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>6 aut.</sZ></inist:fA14><country>Espagne</country><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Joura, E A" uniqKey="Joura E">E. A. Joura</name><affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Gynaecology and Obstetrics, Medical University of Vienna, Comprehensive Cancer Center</s1><s2>Vienna</s2><s3>AUT</s3><sZ>7 aut.</sZ></inist:fA14><country>Autriche</country><wicri:noRegion>Vienna</wicri:noRegion></affiliation></author><author><name sortKey="Maldonado, P" uniqKey="Maldonado P">P. Maldonado</name><affiliation wicri:level="3"><inist:fA14 i1="07"><s1>Instituto de Ginecologia da Universidad Federal Do Rio de Janeiro- UFRJ</s1><s2>Rio de Janeiro</s2><s3>BRA</s3><sZ>8 aut.</sZ></inist:fA14><country>Brésil</country><placeName><settlement type="city">Rio de Janeiro</settlement><region type="state">État de Rio de Janeiro</region></placeName></affiliation></author><author><name sortKey="Klaustermeier, J" uniqKey="Klaustermeier J">J. Klaustermeier</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>9 aut.</sZ><sZ>14 aut.</sZ><sZ>33 aut.</sZ><sZ>35 aut.</sZ><sZ>36 aut.</sZ></inist:fA14><country>Espagne</country><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CIBER en Epidemiología y Salud Pública (CIBERESP)</s1><s3>ESP</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>35 aut.</sZ></inist:fA14><country>Espagne</country><wicri:noRegion>CIBER en Epidemiología y Salud Pública (CIBERESP)</wicri:noRegion></affiliation></author><author><name sortKey="Salmeron, J" uniqKey="Salmeron J">J. Salmeron</name><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Mexican Oncology Hospital, IMSS</s1><s2>Mexico, DF</s2><s3>MEX</s3><sZ>5 aut.</sZ><sZ>10 aut.</sZ></inist:fA14><country>Mexique</country><wicri:noRegion>Mexico, DF</wicri:noRegion></affiliation></author><author><name sortKey="Bergeron, C" uniqKey="Bergeron C">C. Bergeron</name><affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Laboratoire Cerba, Department de Pathologie</s1><s2>Paris</s2><s3>FRA</s3><sZ>11 aut.</sZ></inist:fA14><country>France</country><placeName><region type="région">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Petry, K U" uniqKey="Petry K">K. U. Petry</name><affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Klinikum Wolfsburg</s1><s2>Woljsburg</s2><s3>DEU</s3><sZ>12 aut.</sZ></inist:fA14><country>Allemagne</country><wicri:noRegion>Woljsburg</wicri:noRegion><wicri:noRegion>Klinikum Wolfsburg</wicri:noRegion><wicri:noRegion>Klinikum Wolfsburg</wicri:noRegion></affiliation></author><author><name sortKey="Guimera, N" uniqKey="Guimera N">N. Guimera</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>DDL Diagnostic Laboratory</s1><s2>Rijswijk</s2><s3>NLD</s3><sZ>13 aut.</sZ><sZ>18 aut.</sZ><sZ>32 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>DDL Diagnostic Laboratory</wicri:noRegion></affiliation></author><author><name sortKey="Clavero, O" uniqKey="Clavero O">O. Clavero</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>9 aut.</sZ><sZ>14 aut.</sZ><sZ>33 aut.</sZ><sZ>35 aut.</sZ><sZ>36 aut.</sZ></inist:fA14><country>Espagne</country><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Murillo, R" uniqKey="Murillo R">R. Murillo</name><affiliation wicri:level="1"><inist:fA14 i1="11"><s1>Instituto Nacional de Cancerología</s1><s2>Bogotá</s2><s3>COL</s3><sZ>15 aut.</sZ></inist:fA14><country>Colombie</country><wicri:noRegion>Instituto Nacional de Cancerología</wicri:noRegion></affiliation></author><author><name sortKey="Clavel, C" uniqKey="Clavel C">C. Clavel</name><affiliation wicri:level="1"><inist:fA14 i1="12"><s1>CHU Reims, Hopital Maison Blanche, Laboratoire Pol Bouin</s1><s2>Reims</s2><s3>FRA</s3><sZ>16 aut.</sZ></inist:fA14><country>France</country><placeName><region type="région">Champagne-Ardenne</region><settlement type="city">Reims</settlement></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="13"><s1>INSERM UMR-S903</s1><s2>Reims</s2><s3>FRA</s3><sZ>16 aut.</sZ></inist:fA14><country>France</country><placeName><region type="région">Champagne-Ardenne</region><settlement type="city">Reims</settlement></placeName></affiliation></author><author><name sortKey="Wain, V" uniqKey="Wain V">V. Wain</name><affiliation wicri:level="1"><inist:fA14 i1="14"><s1>WestMead Hospital</s1><s2>Sydney</s2><s3>AUS</s3><sZ>17 aut.</sZ></inist:fA14><country>Australie</country><wicri:noRegion>WestMead Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Geraets, D T" uniqKey="Geraets D">D. T. Geraets</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>DDL Diagnostic Laboratory</s1><s2>Rijswijk</s2><s3>NLD</s3><sZ>13 aut.</sZ><sZ>18 aut.</sZ><sZ>32 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>DDL Diagnostic Laboratory</wicri:noRegion></affiliation></author><author><name sortKey="Jach, R" uniqKey="Jach R">R. Jach</name><affiliation wicri:level="1"><inist:fA14 i1="15"><s1>Jagiellonian University Medical College</s1><s2>Krakow</s2><s3>POL</s3><sZ>19 aut.</sZ></inist:fA14><country>Pologne</country><wicri:noRegion>Jagiellonian University Medical College</wicri:noRegion></affiliation></author><author><name sortKey="Cross, P" uniqKey="Cross P">P. Cross</name><affiliation wicri:level="1"><inist:fA14 i1="16"><s1>Queen Elizabeth Hospital</s1><s2>Sheriff Hill</s2><s3>GBR</s3><sZ>20 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Queen Elizabeth Hospital</wicri:noRegion></affiliation></author><author><name sortKey="Carrilho, C" uniqKey="Carrilho C">C. Carrilho</name><affiliation wicri:level="1"><inist:fA14 i1="17"><s1>Faculty of Medicine, Eduardo Mondlane University and Maputo Central Hospital</s1><s2>Maputo</s2><s3>MOZ</s3><sZ>21 aut.</sZ></inist:fA14><country>Mozambique</country><wicri:noRegion>Maputo</wicri:noRegion></affiliation></author><author><name sortKey="Molina, C" uniqKey="Molina C">C. Molina</name><affiliation wicri:level="1"><inist:fA14 i1="18"><s1>Centro de Oncología Preventiva, Universidad de Chile</s1><s2>Santiago</s2><s3>CHL</s3><sZ>22 aut.</sZ></inist:fA14><country>Chili</country><wicri:noRegion>Santiago</wicri:noRegion></affiliation></author><author><name sortKey="Shin, H R" uniqKey="Shin H">H. R. Shin</name><affiliation wicri:level="3"><inist:fA14 i1="19"><s1>National Cancer Center</s1><s2>Seoul</s2><s3>KOR</s3><sZ>23 aut.</sZ></inist:fA14><country>Corée du Sud</country><placeName><settlement type="city">Séoul</settlement></placeName></affiliation></author><author><name sortKey="Mandys, V" uniqKey="Mandys V">V. Mandys</name><affiliation wicri:level="3"><inist:fA14 i1="20"><s1>Third Faculty of Medicine and Faculty Hospital King's Wineyards</s1><s2>Prague</s2><s3>CZE</s3><sZ>24 aut.</sZ></inist:fA14><country>République tchèque</country><placeName><settlement type="city">Prague</settlement><region type="région" nuts="2">Bohême centrale</region></placeName></affiliation></author><author><name sortKey="Nowakowski, A M" uniqKey="Nowakowski A">A. M. Nowakowski</name><affiliation wicri:level="1"><inist:fA14 i1="21"><s1>Medical University of Lublin</s1><s2>Lublin</s2><s3>POL</s3><sZ>25 aut.</sZ></inist:fA14><country>Pologne</country><wicri:noRegion>Medical University of Lublin</wicri:noRegion></affiliation></author><author><name sortKey="Vidal, A" uniqKey="Vidal A">A. Vidal</name><affiliation wicri:level="3"><inist:fA14 i1="22"><s1>Hospital Universitari de Bellvitge</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>26 aut.</sZ></inist:fA14><country>Espagne</country><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Lombardi, L" uniqKey="Lombardi L">L. Lombardi</name><affiliation wicri:level="1"><inist:fA14 i1="23"><s1>Centro de Investigación Epidemiológica en Salud Sexual y Reproductiva - CIESAR, Hospital General San Juan de Dios - HGSJDD</s1><s2>Guatemala</s2><s3>GTM</s3><sZ>27 aut.</sZ></inist:fA14><country>Guatemala</country><wicri:noRegion>Guatemala</wicri:noRegion></affiliation></author><author><name sortKey="Kitchener, H" uniqKey="Kitchener H">H. Kitchener</name><affiliation wicri:level="1"><inist:fA14 i1="24"><s1>Manchester Royal Infirmary</s1><s2>Manchester</s2><s3>GBR</s3><sZ>28 aut.</sZ></inist:fA14><country>Royaume-Uni</country><wicri:noRegion>Manchester Royal Infirmary</wicri:noRegion></affiliation></author><author><name sortKey="Sica, A R" uniqKey="Sica A">A. R. Sica</name><affiliation wicri:level="1"><inist:fA14 i1="25"><s1>Laboratorio de Anatomia Patológica del Hospital de la Mujer</s1><s2>Montevideo</s2><s3>URY</s3><sZ>29 aut.</sZ></inist:fA14><country>Uruguay</country><wicri:noRegion>Laboratorio de Anatomia Patológica del Hospital de la Mujer</wicri:noRegion></affiliation></author><author><name sortKey="Magana Leon, C" uniqKey="Magana Leon C">C. Magana-Leon</name></author><author><name sortKey="Pawlita, M" uniqKey="Pawlita M">M. Pawlita</name></author><author><name sortKey="Quint, W" uniqKey="Quint W">W. Quint</name><affiliation wicri:level="1"><inist:fA14 i1="10"><s1>DDL Diagnostic Laboratory</s1><s2>Rijswijk</s2><s3>NLD</s3><sZ>13 aut.</sZ><sZ>18 aut.</sZ><sZ>32 aut.</sZ></inist:fA14><country>Pays-Bas</country><wicri:noRegion>DDL Diagnostic Laboratory</wicri:noRegion></affiliation></author><author><name sortKey="Bravo, I G" uniqKey="Bravo I">I. G. Bravo</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>9 aut.</sZ><sZ>14 aut.</sZ><sZ>33 aut.</sZ><sZ>35 aut.</sZ><sZ>36 aut.</sZ></inist:fA14><country>Espagne</country><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author><author><name sortKey="Munoz, N" uniqKey="Munoz N">N. Munoz</name></author><author><name sortKey="De Sanjose, S" uniqKey="De Sanjose S">S. De Sanjose</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>9 aut.</sZ><sZ>14 aut.</sZ><sZ>33 aut.</sZ><sZ>35 aut.</sZ><sZ>36 aut.</sZ></inist:fA14><country>Espagne</country><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>CIBER en Epidemiología y Salud Pública (CIBERESP)</s1><s3>ESP</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>35 aut.</sZ></inist:fA14><country>Espagne</country><wicri:noRegion>CIBER en Epidemiología y Salud Pública (CIBERESP)</wicri:noRegion></affiliation></author><author><name sortKey="Bosch, F X" uniqKey="Bosch F">F. X. Bosch</name><affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>9 aut.</sZ><sZ>14 aut.</sZ><sZ>33 aut.</sZ><sZ>35 aut.</sZ><sZ>36 aut.</sZ></inist:fA14><country>Espagne</country><placeName><settlement type="city">Barcelone</settlement><region nuts="2" type="region">Catalogne</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="inist">14-0256885</idno><date when="2014">2014</date><idno type="stanalyst">PASCAL 14-0256885 INIST</idno><idno type="RBID">Pascal:14-0256885</idno><idno type="wicri:Area/Main/Corpus">000014</idno><idno type="wicri:Area/Main/Curation">002833</idno><idno type="wicri:Area/Main/Exploration">000130</idno></publicationStmt><seriesStmt><idno type="ISSN">0959-8049</idno><title level="j" type="abbreviated">Eur. j. cancer : (1990)</title><title level="j" type="main">European journal of cancer : (1990)</title></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cancerology</term><term>Human papillomavirus</term><term>Intraepithelial neoplasia</term><term>Lesion</term><term>Malignant tumor</term><term>Vaccine</term><term>Vagina</term><term>Vaginal cancer</term><term>Viral disease</term><term>World</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Tumeur maligne</term><term>Papillomavirus humain</term><term>Virose</term><term>Vagin</term><term>Lésion</term><term>Monde</term><term>Néoplasie intraépithéliale</term><term>Vaccin</term><term>Cancérologie</term><term>Cancer du vagin</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Aim: This work describes the human papillomavirus (HPV) prevalence and the HPV type distribution in a large series of vaginal intraepithelial neoplasia (VAIN) grades 2/3 and vaginal cancer worldwide. Methods: We analysed 189 VAIN 2/3 and 408 invasive vaginal cancer cases collected from 31 countries from 1986 to 2011. After histopathological evaluation of sectioned formalin-fixed paraffin-embedded samples, HPV DNA detection and typing was performed using the SPF-10/DNA enzyme immunoassay (DEIA)/LiPA<sub>25</sub> system (version 1). A subset of 146 vaginal cancers was tested for p16<sup>INK4a</sup> expression, a cellular surrogate marker for HPV transformation. Prevalence ratios were estimated using multivariate Poisson regression with robust variance. Results: HPV DNA was detected in 74% (95% confidence interval (CI): 70-78%) of invasive cancers and in 96% (95% CI: 92-98%) of VAIN 2/3. Among cancers, the highest detection rates were observed in warty-basaloid subtype of squamous cell carcinomas, and in younger ages. Concerning the type-specific distribution, HPV16 was the most frequently type detected in both precancerous and cancerous lesions (59%). p16<sup>INK4a</sup> overexpression was found in 87% of HPV DNA positive vaginal cancer cases. Conclusions: HPV was identified in a large proportion of invasive vaginal cancers and in almost all VAIN 2/3. HPV16 was the most common type detected. A large impact in the reduction of the burden of vaginal neoplastic lesions is expected among vaccinated cohorts.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0959-8049</s0></fA01><fA03 i2="1"><s0>Eur. j. cancer : (1990)</s0></fA03><fA05><s2>50</s2></fA05><fA06><s2>16</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Large contribution of human papillomavirus in vaginal neoplastic lesions: A worldwide study in 597 samples</s1></fA08><fA11 i1="01" i2="1"><s1>ALEMANY (L.)</s1></fA11><fA11 i1="02" i2="1"><s1>SAUNIER (M.)</s1></fA11><fA11 i1="03" i2="1"><s1>TINOCO (L.)</s1></fA11><fA11 i1="04" i2="1"><s1>QUIROS (B.)</s1></fA11><fA11 i1="05" i2="1"><s1>ALVARADO-CABRERO (I.)</s1></fA11><fA11 i1="06" i2="1"><s1>ALEJO (M.)</s1></fA11><fA11 i1="07" i2="1"><s1>JOURA (E. A.)</s1></fA11><fA11 i1="08" i2="1"><s1>MALDONADO (P.)</s1></fA11><fA11 i1="09" i2="1"><s1>KLAUSTERMEIER (J.)</s1></fA11><fA11 i1="10" i2="1"><s1>SALMERON (J.)</s1></fA11><fA11 i1="11" i2="1"><s1>BERGERON (C.)</s1></fA11><fA11 i1="12" i2="1"><s1>PETRY (K. U.)</s1></fA11><fA11 i1="13" i2="1"><s1>GUIMERA (N.)</s1></fA11><fA11 i1="14" i2="1"><s1>CLAVERO (O.)</s1></fA11><fA11 i1="15" i2="1"><s1>MURILLO (R.)</s1></fA11><fA11 i1="16" i2="1"><s1>CLAVEL (C.)</s1></fA11><fA11 i1="17" i2="1"><s1>WAIN (V.)</s1></fA11><fA11 i1="18" i2="1"><s1>GERAETS (D. T.)</s1></fA11><fA11 i1="19" i2="1"><s1>JACH (R.)</s1></fA11><fA11 i1="20" i2="1"><s1>CROSS (P.)</s1></fA11><fA11 i1="21" i2="1"><s1>CARRILHO (C.)</s1></fA11><fA11 i1="22" i2="1"><s1>MOLINA (C.)</s1></fA11><fA11 i1="23" i2="1"><s1>SHIN (H. R.)</s1></fA11><fA11 i1="24" i2="1"><s1>MANDYS (V.)</s1></fA11><fA11 i1="25" i2="1"><s1>NOWAKOWSKI (A. M.)</s1></fA11><fA11 i1="26" i2="1"><s1>VIDAL (A.)</s1></fA11><fA11 i1="27" i2="1"><s1>LOMBARDI (L.)</s1></fA11><fA11 i1="28" i2="1"><s1>KITCHENER (H.)</s1></fA11><fA11 i1="29" i2="1"><s1>SICA (A. R.)</s1></fA11><fA11 i1="30" i2="1"><s1>MAGANA-LEON (C.)</s1></fA11><fA11 i1="31" i2="1"><s1>PAWLITA (M.)</s1></fA11><fA11 i1="32" i2="1"><s1>QUINT (W.)</s1></fA11><fA11 i1="33" i2="1"><s1>BRAVO (I. G.)</s1></fA11><fA11 i1="34" i2="1"><s1>MUNOZ (N.)</s1></fA11><fA11 i1="35" i2="1"><s1>DE SANJOSE (S.)</s1></fA11><fA11 i1="36" i2="1"><s1>BOSCH (F. X.)</s1></fA11><fA14 i1="01"><s1>Unit of Infections and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>4 aut.</sZ><sZ>6 aut.</sZ><sZ>9 aut.</sZ><sZ>14 aut.</sZ><sZ>33 aut.</sZ><sZ>35 aut.</sZ><sZ>36 aut.</sZ></fA14><fA14 i1="02"><s1>CIBER en Epidemiología y Salud Pública (CIBERESP)</s1><s3>ESP</s3><sZ>1 aut.</sZ><sZ>9 aut.</sZ><sZ>35 aut.</sZ></fA14><fA14 i1="03"><s1>Hospital Oncológico</s1><s2>Quito</s2><s3>ECU</s3><sZ>3 aut.</sZ></fA14><fA14 i1="04"><s1>Mexican Oncology Hospital, IMSS</s1><s2>Mexico, DF</s2><s3>MEX</s3><sZ>5 aut.</sZ><sZ>10 aut.</sZ></fA14><fA14 i1="05"><s1>Hospital General de L'Hospitalet</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>6 aut.</sZ></fA14><fA14 i1="06"><s1>Department of Gynaecology and Obstetrics, Medical University of Vienna, Comprehensive Cancer Center</s1><s2>Vienna</s2><s3>AUT</s3><sZ>7 aut.</sZ></fA14><fA14 i1="07"><s1>Instituto de Ginecologia da Universidad Federal Do Rio de Janeiro- UFRJ</s1><s2>Rio de Janeiro</s2><s3>BRA</s3><sZ>8 aut.</sZ></fA14><fA14 i1="08"><s1>Laboratoire Cerba, Department de Pathologie</s1><s2>Paris</s2><s3>FRA</s3><sZ>11 aut.</sZ></fA14><fA14 i1="09"><s1>Klinikum Wolfsburg</s1><s2>Woljsburg</s2><s3>DEU</s3><sZ>12 aut.</sZ></fA14><fA14 i1="10"><s1>DDL Diagnostic Laboratory</s1><s2>Rijswijk</s2><s3>NLD</s3><sZ>13 aut.</sZ><sZ>18 aut.</sZ><sZ>32 aut.</sZ></fA14><fA14 i1="11"><s1>Instituto Nacional de Cancerología</s1><s2>Bogotá</s2><s3>COL</s3><sZ>15 aut.</sZ></fA14><fA14 i1="12"><s1>CHU Reims, Hopital Maison Blanche, Laboratoire Pol Bouin</s1><s2>Reims</s2><s3>FRA</s3><sZ>16 aut.</sZ></fA14><fA14 i1="13"><s1>INSERM UMR-S903</s1><s2>Reims</s2><s3>FRA</s3><sZ>16 aut.</sZ></fA14><fA14 i1="14"><s1>WestMead Hospital</s1><s2>Sydney</s2><s3>AUS</s3><sZ>17 aut.</sZ></fA14><fA14 i1="15"><s1>Jagiellonian University Medical College</s1><s2>Krakow</s2><s3>POL</s3><sZ>19 aut.</sZ></fA14><fA14 i1="16"><s1>Queen Elizabeth Hospital</s1><s2>Sheriff Hill</s2><s3>GBR</s3><sZ>20 aut.</sZ></fA14><fA14 i1="17"><s1>Faculty of Medicine, Eduardo Mondlane University and Maputo Central Hospital</s1><s2>Maputo</s2><s3>MOZ</s3><sZ>21 aut.</sZ></fA14><fA14 i1="18"><s1>Centro de Oncología Preventiva, Universidad de Chile</s1><s2>Santiago</s2><s3>CHL</s3><sZ>22 aut.</sZ></fA14><fA14 i1="19"><s1>National Cancer Center</s1><s2>Seoul</s2><s3>KOR</s3><sZ>23 aut.</sZ></fA14><fA14 i1="20"><s1>Third Faculty of Medicine and Faculty Hospital King's Wineyards</s1><s2>Prague</s2><s3>CZE</s3><sZ>24 aut.</sZ></fA14><fA14 i1="21"><s1>Medical University of Lublin</s1><s2>Lublin</s2><s3>POL</s3><sZ>25 aut.</sZ></fA14><fA14 i1="22"><s1>Hospital Universitari de Bellvitge</s1><s2>Barcelona</s2><s3>ESP</s3><sZ>26 aut.</sZ></fA14><fA14 i1="23"><s1>Centro de Investigación Epidemiológica en Salud Sexual y Reproductiva - CIESAR, Hospital General San Juan de Dios - HGSJDD</s1><s2>Guatemala</s2><s3>GTM</s3><sZ>27 aut.</sZ></fA14><fA14 i1="24"><s1>Manchester Royal Infirmary</s1><s2>Manchester</s2><s3>GBR</s3><sZ>28 aut.</sZ></fA14><fA14 i1="25"><s1>Laboratorio de Anatomia Patológica del Hospital de la Mujer</s1><s2>Montevideo</s2><s3>URY</s3><sZ>29 aut.</sZ></fA14><fA17 i1="01" i2="1"><s1>HPV VVAP study group</s1><s3>INC</s3></fA17><fA20><s1>2846-2854</s1></fA20><fA21><s1>2014</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>12648</s2><s5>354000502656940130</s5></fA43><fA44><s0>0000</s0><s1>© 2014 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>28 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>14-0256885</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>European journal of cancer : (1990)</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>Aim: This work describes the human papillomavirus (HPV) prevalence and the HPV type distribution in a large series of vaginal intraepithelial neoplasia (VAIN) grades 2/3 and vaginal cancer worldwide. Methods: We analysed 189 VAIN 2/3 and 408 invasive vaginal cancer cases collected from 31 countries from 1986 to 2011. After histopathological evaluation of sectioned formalin-fixed paraffin-embedded samples, HPV DNA detection and typing was performed using the SPF-10/DNA enzyme immunoassay (DEIA)/LiPA<sub>25</sub> system (version 1). A subset of 146 vaginal cancers was tested for p16<sup>INK4a</sup> expression, a cellular surrogate marker for HPV transformation. Prevalence ratios were estimated using multivariate Poisson regression with robust variance. Results: HPV DNA was detected in 74% (95% confidence interval (CI): 70-78%) of invasive cancers and in 96% (95% CI: 92-98%) of VAIN 2/3. Among cancers, the highest detection rates were observed in warty-basaloid subtype of squamous cell carcinomas, and in younger ages. Concerning the type-specific distribution, HPV16 was the most frequently type detected in both precancerous and cancerous lesions (59%). p16<sup>INK4a</sup> overexpression was found in 87% of HPV DNA positive vaginal cancer cases. Conclusions: HPV was identified in a large proportion of invasive vaginal cancers and in almost all VAIN 2/3. HPV16 was the most common type detected. A large impact in the reduction of the burden of vaginal neoplastic lesions is expected among vaccinated cohorts.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02</s0></fC02><fC02 i1="02" i2="X"><s0>002B04C</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Tumeur maligne</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Malignant tumor</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Tumor maligno</s0><s2>NM</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Papillomavirus humain</s0><s2>NW</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Human papillomavirus</s0><s2>NW</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Human papillomavirus</s0><s2>NW</s2><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Virose</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Viral disease</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Virosis</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Vagin</s0><s5>05</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Vagina</s0><s5>05</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Vagina</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Lésion</s0><s5>06</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Lesion</s0><s5>06</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Lesión</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Monde</s0><s2>NG</s2><s5>08</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>World</s0><s2>NG</s2><s5>08</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Mundo</s0><s2>NG</s2><s5>08</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Néoplasie intraépithéliale</s0><s2>NM</s2><s5>09</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Intraepithelial neoplasia</s0><s2>NM</s2><s5>09</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Neoplasia intraepitelial</s0><s2>NM</s2><s5>09</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Vaccin</s0><s5>11</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Vaccine</s0><s5>11</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Vacuna</s0><s5>11</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Cancérologie</s0><s5>12</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Cancerology</s0><s5>12</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Cancerología</s0><s5>12</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Cancer du vagin</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Vaginal cancer</s0><s4>CD</s4><s5>96</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Cáncer de vagina</s0><s4>CD</s4><s5>96</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Cáncer</s0><s2>NM</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Papillomavirus</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Papillomavirus</s0><s2>NW</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Papillomavirus</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Papovaviridae</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Papovaviridae</s0><s2>NW</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Papovaviridae</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Infection</s0></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Infection</s0></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Infección</s0></fC07><fN21><s1>315</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=FranceBresilV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000130 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000130 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= FranceBresilV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:14-0256885
|texte= Large contribution of human papillomavirus in vaginal neoplastic lesions: A worldwide study in 597 samples
}}
| This area was generated with Dilib version V0.6.01. |  |